Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Title
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Authors
Keywords
SCLC, Third-line, Nivolumab, PD-1 inhibitor, Immunotherapy
Journal
Journal of Thoracic Oncology
Volume 14, Issue 2, Pages 237-244
Publisher
Elsevier BV
Online
2018-10-11
DOI
10.1016/j.jtho.2018.10.003

Ask authors/readers for more resources

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started